4D Molecular Therapeutics (FDMT) FCF Margin (2020 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly FCF Margin of 2235.81% for Q1 2026, up 33989277.0% year-over-year from N/an in Q1 2025, and down 7951.62% quarter-over-quarter from 28.48% in Q4 2025.
Powered by 
Analysis
4D Molecular Therapeutics (FDMT) FCF Margin (2020 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported FCF Margin for 7 consecutive years, with 2235.81% the latest figure, recorded in Q1 2026.
- In Q1 2026, FCF Margin rose 33989277.0% year-over-year to 2235.81%; the TTM figure through Mar 2026 stood at 152.12% (up 68015657.0% YoY), while the FY2025 annual figure was 133.8%, up 37384188.0% from the prior year.
- FCF Margin eased to 2235.81% in Q1 2026 per FDMT's latest filing, from 28.48% in the prior quarter.
- Across five years, FCF Margin topped out at 119273.68% in Q4 2023 and bottomed at 4681200.0% in Q4 2024.
- Historically, FCF Margin has averaged 414527.6% across 5 years, with a median of 9704.03% in 2023.
- Annual changes were most pronounced in 2024 — FCF Margin sank 480047368 bps — and 2025, when it jumped 468122848 bps.
- 4D Molecular Therapeutics' FCF Margin stood at 1746.11% in 2022, then jumped by 6931 bps to 119273.68% in 2023, then tumbled by 4025 bps to 4681200.0% in 2024, then jumped by 100 bps to 28.48% in 2025, then slumped by 7952 bps to 2235.81% in 2026.
- Business Quant data shows FDMT's FCF Margin at 2235.81% in Q1 2026, 28.48% in Q4 2025, and 51563.33% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | 4D Molecular Therapeutics | 1.05 Bn | 692.04 Mn | - | -1,850.86% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,850.86% |
| Mar 31, 2026 | -2,257.79% |
| Dec 31, 2025 | 33.78% |
| Sep 30, 2025 | -51,653.33% |
| Jun 30, 2025 | -304,826.67% |
| Mar 31, 2025 | -361,000.00% |
| Dec 31, 2024 | -4,681,200.00% |
| Sep 30, 2024 | -1,019,733.33% |
| Jun 30, 2024 | -623,380.00% |
| Mar 31, 2024 | -106,421.43% |
| Dec 31, 2023 | 132,626.32% |
| Sep 30, 2023 | -7.80% |
| Jun 30, 2023 | -9,569.04% |
| Mar 31, 2023 | -9,704.03% |
| Dec 31, 2022 | -1,869.05% |
| Sep 30, 2022 | -4,596.20% |
| Jun 30, 2022 | -13,561.73% |
| Mar 31, 2022 | -2,458.00% |
| Dec 31, 2021 | -29,273.91% |
| Sep 30, 2021 | -1,343.78% |